STX‐100 (BG00011): STX‐100 is an integrin αvβ6 mAb that partially inhibits TGF‐β and blocks murine pulmonary fibrosis without exacerbating inflammation.[529] Multiple phase II clinical trials have been conducted to evaluate the safety and efficacy of STX‐100 in IPF patients (NCT03573505, NCT01371305). This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.